Hyoscyamine Sulfate Drops Rx
Generic Name and Formulations:
Hyoscyamine sulfate 0.125mg/mL; alcohol 5%; orange flavor.
Various generic manufacturers
Indications for Hyoscyamine Sulfate Drops:
Adjunct in peptic ulcer. Irritable bowel syndrome. Infant colic.
1–2mL every 4 hrs or as needed; max 12mL/day.
3.4kg: 4 drops. 5kg: 5 drops. 7kg: 6 drops. 10kg: 8 drops. Older children (2 yrs–12 yrs): 0.25–1mL; max 6mL/day. All: every 4 hrs or as needed.
Glaucoma. Unstable cardiovascular status in acute hemorrhage. GI or urinary tract obstruction. Paralytic ileus, intestinal atony of elderly or debilitated patients. Toxic megacolon. Severe ulcerative colitis. Myasthenia gravis.
High environmental temperature. Diarrhea. Autonomic neuropathy. Impaired cardiac or renal function. Cardiovascular disease. Hypertension. Hyperthyroidism. Hiatal hernia with reflux esophagitis. Pregnancy (Cat.C). Nursing mothers.
Antacids may inhibit absorption. Additive anticholinergic effects with other anticholinergics, amantadine, type I antiarrhythmics, antihistamines, phenothiazines, tricyclics, MAOIs.
Anticholinergic effects, drowsiness.
Formerly known under the brand name Levsin Drops.
Tabs, SL—100, 500; Drops—contact supplier
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response
- Higher-Dose Immunoglobulin Replacement Therapy in Chronic Lymphocytic Leukemia
- Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers
- Finding Clinical Trials in Cancer
- Combining Chemotherapy With Checkpoint Inhibitors Extends Overall Survival in ES-SCLC
- In a Head-to-Head Battle, Brigatinib Appears to Best Crizotinib
- Durvalumab Shows Overall Survival Benefit in Patients With Stage III NSCLC
- Baseline Thrombopoietin Levels May Help Predict Response to ITP Treatment
- Despite Promising Trial Results, Skeptics Raise Red Flags About Anlotinib's Efficacy in Heavily Treated NSCLC